We can’t tell you much because the information has been fed to the Murdoch press (paywall) and there’s no information that we can yet find on the ATAI website or the supposed Australian Partner, Bionomics.
We’re interested by the timing as the TGA has just turned down re-scheduling MDMA & Psilocybin so are they waiting for Mind Medicine to do all the hard work for them.? Do they have a deal with the South Australian govt ? Will Bionomics be a funnel for Angermeyer to feed in funds to push for re-scheduling and if they are running the story through the Australian we’d guess that it’s all about future listings?
This is the screenshot from the Australian
Here’s the last time Bionomics published a media release so it’s obvious they don’t like sharing information with the great unwashed
Here though, is their board and the message from their Chairman
MESSAGE FROM THE CHAIRMAN
Bionomics is a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders such as anxiety, depression and Alzheimer’s disease.
I invite you to spend a few minutes exploring our website and getting to know us. Our exceptionally talented team is driven by a shared commitment to make a difference in diseases with high unmet need and inadequate treatment options.
We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to mid stages of clinical development. This portfolio is fed by highly productive drug discovery platforms that include MultiCore®, our proprietary chemistry capability.
At the core of our business is strategic partnering. We partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. This means we can focus our strengths in innovative drug discovery to extract as many “shots on goal” from our diverse pipeline in the quest to create the world’s new blockbuster drugs.
We have a passion for what we do and we work with the best in the world to deliver meaningful outcomes from our discoveries. We look forward to you accompanying us on this extremely valuable journey.
Dr Errol DeSouza PhD
Dr Errol De Souza PhD
Dr De Souza is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders. He has substantial experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Sciences Inc.) and served as President and CEO of several public (Biodel Inc; Synaptic Pharmaceutical) and private (Archemix Corp. and Neuropore Therapies Inc.) biotech companies. Dr. De Souza has raised several hundred million dollars in capital in private and public sectors and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic sale to Lundbeck) to provide liquidity and build shareholder value. Over Dr. De Souza’s career, he has served in a number of high-ranking R&D roles, including SVP and U.S. head of Aventis (1998-2002), co-founder and EVP of R&D at Neurocrine (1992-1998) and Head of CNS at DuPont Merck (1990-1992).
Dr De Souza has served on multiple editorial boards, National Institutes of Health (NIH) Committees and is currently a Director of several public and private companies and currently serves as a member of the board of directors of Catalyst Biosciences (CBIO). He has previously served on the board of directors of several public companies including IDEXX Laboratories (IDXX), Neurocrine Biosciences (NBIX), Palatin Technologies (PTN) and Synaptic Pharmaceuticals (SNAP).
Mr David Wilson
Mr Wilson is Chairman and founding partner of WG Partners and has over 30 years’ experience in the City of London. Previously he was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. He was previously Senior Independent Director of Optos plc prior to its successful sale of Nikon Corporation for c.$400m as well as a non-executive director of BerGenBio AS. He is currently on the Board of Governors of Harris Academy Bromley.
Mr Alan Fisher BCom, FCA, MAICD
Mr Fisher has extensive and proven experience in restoring and enhancing shareholder value. He spent 24 years at world-leading accounting firm Coopers & Lybrand as Lead Advisory Partner where he headed and grew the Melbourne Corporate Finance Division. Following this tenure Mr Fisher developed his own business as a corporate advisor and for the past 19 years has specialised in M&A, business restructurings, strategic advice and capital raisings for small cap companies. He is currently Non-Executive Chairman of Centrepoint Alliance Limited, and Chair of IDT Australia Limited. He is also the Managing Director of DMC Corporate. He holds a Bachelor of Commerce from Melbourne University, is a Fellow of the Institute of Chartered Accountants Australia and a Member of the Australian Institute of Company Directors.
Mr Mitchell Kaye
Mitchell Kaye, J.D., joined BVF Partners L.P. in 2013. Mr. Kaye was the founding member of Xmark Opportunity Partners, LLC, an investment fund exclusively focused on investments in publicly traded life sciences companies and was also a founding member of Brown Simpson Asset Management, LLC, an investment fund that was at the foreground of private placement investing in the public markets. He ran the two funds from 2001-2008 and 1996-2001, respectively. Mr. Kaye was the Founder of MedClaims Liaison, LLC, a consumer advocacy business, and served as its Chief Executive Officer from its inception in 2010 until he joined BVF. From 2008-2010, Mr. Kaye was a Managing Director with Navigant Capital Advisors, a financial and strategic advisory services firm, and head of Navigant’s Financial Institutions Restructuring Solutions Team. Mr. Kaye currently serves on the board of Bionomics. He has served on the boards of several private and public companies, as well as the board of the New York Alzheimer’s Association. Mr. Kaye received his B.A. from Wesleyan University, and his J.D. from Northwestern University School of Law.
Mr Aaron Weaver CFA, LLM
Mr Weaver is a Managing Director at Apeiron Investments focused on the life sciences sector. He also serves as Senior General Counsel and supports fundraising and investor relations activities at ATAI Life Sciences AG, a clinical stage biopharmaceutical company focused on the development of therapeutics for the treatment of mood disorders, addiction and anxiety. He is a Chartered Financial Analyst (CFA) and a registered solicitor in the United Kingdom. From 2013 – 2017, he was an investment banker at Credit Suisse in London within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies. He was a capital markets solicitor at Allen & Overy LLP, London from 2007 – 2013. He holds a Masters of Law from the Queensland University of Technology and a Bachelor of Business Administration from the University of Queensland.
Jane Ryan PhD
Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries where she has held executive roles in management of research and development programs as well as business development and alliance management. Having worked in Australia, the US and Uk with compnaies including Peptech, Roche, Cambridge Antibody Technology and Biota Holdings, throughout her career, she has led many successful fundraising campaigns and licensing initiatives inclusive of a $230M US Government contract. Dr Ryan has an interest in public health and the advancement of science and currently chairs the Advisory Board of the ithree Institute at the University of Technology Sydney (UTS), and was previously a Board Member of the Veski, Diabetes Victoria, TechInSA, and the Diabetes Vaccine Development Centre.
Dr Srinivas Rao MD, PhD
Dr Srinivas Rao is the Chief Scientific Officer at atai Life Sciences AG. Dr Rao has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to atai, Dr Rao has held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture backed startups to vertically-integrated, publicly traded pharmaceutical companies. Dr Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. He received his Phd in neurobiology from Yale Graduate School and his MD from Yale School of Medicine. He holds both a Bachelor of Science and Master of Science degree in Electrical Engineering from Yale College and Yale Graduate School, respectively.
They do of course have a state of the art facility… i mean who doesn’t these days !